Cytotoxicity News and Research

RSS
Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

U of S-led researchers develop novel class of compounds for effective cancer treatment

U of S-led researchers develop novel class of compounds for effective cancer treatment

STING agonists developed to induce cellular death in B cell malignancies

STING agonists developed to induce cellular death in B cell malignancies

Covestro to showcase high-performance materials for medical applications at MD&M West 2016

Covestro to showcase high-performance materials for medical applications at MD&M West 2016

Excess folic acid intake causes lowered immune function in aged mice

Excess folic acid intake causes lowered immune function in aged mice

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

NRL researchers to develop next generation of functional materials to map brain connections

NRL researchers to develop next generation of functional materials to map brain connections

Weight cycling not associated with overall risk of cancer

Weight cycling not associated with overall risk of cancer

Heidelberg University scientists gain new insight into cytotoxic effect of Ebola virus

Heidelberg University scientists gain new insight into cytotoxic effect of Ebola virus

Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists design a promising vaccine for herpes viruses

Scientists design a promising vaccine for herpes viruses

New type of vaccine holds promise for prevention of genital herpes

New type of vaccine holds promise for prevention of genital herpes

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Bayer launches new polycarbonate blend grade tailored for wearable medical devices

Bayer launches new polycarbonate blend grade tailored for wearable medical devices

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Bayer offers wide range of material solutions for OEMs' medical application needs

Bayer offers wide range of material solutions for OEMs' medical application needs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.